Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

医学 托珠单抗 安慰剂 内科学 双盲 临床试验 梅德林 病理 类风湿性关节炎 法学 政治学 替代医学
作者
Dinesh Khanna,Celia J. F. Lin,Daniel E. Furst,Jonathan Goldin,Grace Kim,Masataka Kuwana,Yannick Allanore,Marco Matucci‐Cerinic,Oliver Distler,Yoshihito Shima,Jacob M. van Laar,Helen Spotswood,Bridget K. Wagner,Jeffrey Siegel,Angelika Jahreis,Christopher P. Denton,Eleonora Lucero,Bernardo A. Pons‐Estel,Mariano Rivero,Guillermo Tate
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:8 (10): 963-974 被引量:521
标识
DOI:10.1016/s2213-2600(20)30318-0
摘要

Summary

Background

A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in systemic sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial lung disease (SSc-ILD) in a phase 3 trial to investigate the safety and efficacy of tocilizumab, an anti-interleukin-6 receptor antibody, in the treatment of systemic sclerosis.

Methods

In this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, participants were recruited from 75 sites in 20 countries across Europe, North America, Latin America, and Japan. Adults with diffuse cutaneous systemic sclerosis for 60 months or less and a modified Rodnan skin score (mRSS) of 10–35 at screening were randomly assigned (1:1) with a voice-web-response system to receive subcutaneous tocilizumab 162 mg or placebo weekly for 48 weeks, stratified by IL-6 levels; participants and investigators were masked to treatment group. The primary endpoint was the difference in change from baseline to week 48 in mRSS. Percentage of predicted forced vital capacity (FVC% predicted) at week 48, time to treatment failure, and patient-reported and physician-reported outcomes were secondary endpoints. This trial is registered with ClinicalTrials.gov (number NCT02453256) and is closed to accrual.

Findings

Between Nov 20, 2015, and Feb 14, 2017, 210 individuals were randomly assigned to receive tocilizumab (n=104) or placebo (n=106). In the intention-to-treat population, least squares mean [LSM] change from baseline to week 48 in mRSS was −6·14 for tocilizumab and −4·41 for placebo (adjusted difference −1·73 [95% CI −3·78 to 0·32]; p=0·10). The shift in distribution of change from baseline in FVC% predicted at week 48 favoured tocilizumab (van Elteren nominal p=0·002 vs placebo), with a difference in LSM of 4·2 (95% CI 2·0–6·4; nominal p=0·0002), as did time to treatment failure (hazard ratio 0·63 [95% CI 0·37–1·06]; nominal p=0·08). Change in LSM from baseline to week 48 in Health Assessment Questionnaire-Disability Index and in patient-global and physician-global visual analogue scale assessments did not differ between tocilizumab and placebo. In the safety set, infections were the most common adverse events (54 [52%] of 104 participants in the tocilizumab group, 53 [50%] of 106 in the placebo group). Serious adverse events were reported in 13 participants treated with tocilizumab and 18 with placebo, primarily infections (three events, eight events) and cardiac events (two events, seven events).

Interpretation

The primary skin fibrosis endpoint was not met. Findings for the secondary endpoint of FVC% predicted indicate that tocilizumab might preserve lung function in people with early SSc-ILD and elevated acute-phase reactants. Safety was consistent with the known profile of tocilizumab.

Funding

F Hoffmann-La Roche Ltd.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Fa完成签到,获得积分10
刚刚
2秒前
2秒前
嘀嘀嘀发布了新的文献求助10
2秒前
2秒前
Charety发布了新的文献求助10
3秒前
3秒前
彭院士发布了新的文献求助20
5秒前
善学以致用应助嘀嘀嘀采纳,获得10
5秒前
有有发布了新的文献求助10
6秒前
DDd发布了新的文献求助20
6秒前
numagok完成签到,获得积分10
7秒前
cmq完成签到 ,获得积分10
7秒前
Cassie发布了新的文献求助10
8秒前
Hello应助阿童木采纳,获得10
10秒前
cc完成签到,获得积分10
10秒前
11秒前
11秒前
12秒前
情怀应助塵埃采纳,获得10
12秒前
zzz完成签到,获得积分20
13秒前
tanXX发布了新的文献求助10
14秒前
FAN发布了新的文献求助30
14秒前
15秒前
17秒前
18秒前
Jaden完成签到,获得积分10
18秒前
笛卡尔完成签到,获得积分10
19秒前
20秒前
20秒前
ikkk完成签到,获得积分20
21秒前
21秒前
Winfred发布了新的文献求助10
22秒前
小南发布了新的文献求助10
23秒前
adsifhaidugw发布了新的文献求助30
23秒前
一一一发布了新的文献求助10
24秒前
25秒前
奇怪的柒发布了新的文献求助10
25秒前
阿童木发布了新的文献求助10
25秒前
英俊的铭应助Superan采纳,获得10
27秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3959547
求助须知:如何正确求助?哪些是违规求助? 3505776
关于积分的说明 11126213
捐赠科研通 3237706
什么是DOI,文献DOI怎么找? 1789252
邀请新用户注册赠送积分活动 871647
科研通“疑难数据库(出版商)”最低求助积分说明 802931